To test our gene editing strategy, we nucleofected the constructs into primary dermal fibroblast cells obtained from four independent patients carrying the COL6A1 c.868G>A (G290R) variant (Pt1 to Pt4), and from one non-neuromuscular disease patient as a control (Ctrl). Here, ZNF77 is linked to neuromuscular disease.